Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours
| Data(s) |
01/12/2011
|
|---|---|
| Resumo |
Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Yan , B , Choo , S N , Mulyadi , P , Srivastava , S , Ong , C W , Yong , K J , Putti , T , Salto-Tellez , M & Lim , G S D 2011 , ' Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours ' Journal of Clinical Pathology , vol 64 , no. 12 , pp. 1097-101 . DOI: 10.1136/jclinpath-2011-200082 |
| Palavras-Chave | #Sensitivity and Specificity #Chromosomes, Human, Pair 17 #Ovarian Neoplasms #Genes, erbB-2 #Receptor, erbB-2 #Humans #Color #Gene Amplification #In Situ Hybridization #Adenocarcinoma, Mucinous #Cohort Studies #Immunohistochemistry #Female |
| Tipo |
article |
